Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE2 | O96020 | 1/20 | 0.37 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.31 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14158926 | 0.83 | CYP2D6 (0.48) | CCNE2CCNE1CDK2ADRB2ADRB1 | |
| SCHEMBL11890836 | 0.82 | KDM4E (0.32) | CCNE2CCNE1CDK2KDM4EMAPK1 | |
| SCHEMBL13411703 | 0.81 | KDM4E (0.43) | KDM4EMAPK1HIF1ANPC1MTNR1A | |
| SCHEMBL19483415 | 0.80 | CCNE2 (0.32) | CCNE2CCNE1CDK2 | |
| SCHEMBL19483406 | 0.80 | CCNE2 (0.32) | CCNE2CCNE1CDK2 | |
| SCHEMBL17019098 | 0.79 | EPHX1 (0.34) | CCNE2CCNE1CDK2ALDH1A1 | |
| SCHEMBL21231186 | 0.78 | MTNR1A (0.37) | KDM4EMAPK1HIF1ANPC1MTNR1A | |
| SCHEMBL804956 | 0.77 | KDM4E (0.33) | KDM4EMAPK1HIF1ANPC1MTNR1A | |
| SCHEMBL15835816 | 0.75 | — | — | |
| SCHEMBL16015603 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11639347-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-05-02 | — | — | US | disclosed |
| US-10022352-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-07-17 | — | — | US | disclosed |
| US-20180162842-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2018-06-14 | — | — | US | disclosed |
| US-20160271105-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2016-09-22 | — | — | US | disclosed |
| US-20150231142-A1 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | VERTEX PHARMA (US) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11639347-B2 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | CCNE2 4640/4885CCNE1 4737/4885CDK2 4395/4885 |
| US-20180162842-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | CCNE2 4640/4885CCNE1 4737/4885CDK2 4395/4885 |
| US-20150231142-A1 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | CFTR, SLC26A4, ABCB11 | CCNE2 4033/4885CCNE1 4317/4885CDK2 4210/4885 |
| US-10022352-B2 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | CCNE2 4640/4885CCNE1 4737/4885CDK2 4395/4885 |
| US-20160271105-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | CCNE2 4640/4885CCNE1 4737/4885CDK2 4395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.